Document is current

Article History

Received: 29 May 2021

Revised: 31 August 2021

Accepted: 17 September 2021

First Online: 29 September 2021

Ethics approval and consent to participate

: The online questionnaire was completely anonymous. An information letter notified the participants that completing the questionnaire infers an inherent agreement to their participation in the study and subsequently a written consent was not required. The study was examined and approved by the internal review board (IRB) at Gustave Roussy, Villejuif, France on April 6, 2020. The study was performed in accordance with the Declaration of Helsinki.

: AB, MK, ER, CL, LV, CU, ED, DG, MS, SG, JG, AP, VD, J-YP, TP, SL, WJ, M-AB, ADJ, SD: None relevant to this study. PEH reports grants, personal fees and non-financial support from PFIZER, grants and non-financial support from NOVARTIS, grants and non-financial support from ROCHE, grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Mylan, grants, personal fees and non-financial support from Pierre Fabre, personal fees and non-financial support from AMGEN and personal fees and non-financial support from SEAGEN. ML acted as a consultant for Roche, Lilly, Novartis and AstraZeneca and received honoraria from Sandoz, Roche, Lilly, Pfizer and Novartis outside the submitted work. BP: consulting/advisor: Puma Biotechnology, Novartis, Myriad Genetics, Pierre Fabre; personal fees: Novartis, AstraZeneca, MSD Oncology, Pfizer; research funding: Daiichi-Sankyo, Puma Biotechnology, Novartis, Merus, Pfizer, AstraZeneca.

Free to read: This content has been made available to all.